InterCure (INCR) Competitors $1.38 +0.01 (+0.36%) Closing price 04/17/2025 03:57 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 04/17/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INCR vs. ENGN, AVIR, ESPR, CADL, ACB, PVLA, IMMP, OLMA, CMPX, and DRUGShould you be buying InterCure stock or one of its competitors? The main competitors of InterCure include enGene (ENGN), Atea Pharmaceuticals (AVIR), Esperion Therapeutics (ESPR), Candel Therapeutics (CADL), Aurora Cannabis (ACB), Palvella Therapeutics (PVLA), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Compass Therapeutics (CMPX), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. InterCure vs. enGene Atea Pharmaceuticals Esperion Therapeutics Candel Therapeutics Aurora Cannabis Palvella Therapeutics Immutep Olema Pharmaceuticals Compass Therapeutics Bright Minds Biosciences enGene (NASDAQ:ENGN) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk. Is ENGN or INCR more profitable? InterCure's return on equity of 0.00% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -16.69% -14.27% InterCure N/A N/A N/A Does the MarketBeat Community prefer ENGN or INCR? enGene received 16 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 95.00% of users gave enGene an outperform vote. CompanyUnderperformOutperformenGeneOutperform Votes1995.00% Underperform Votes15.00%InterCureOutperform Votes3100.00% Underperform VotesNo Votes Do institutionals and insiders hold more shares of ENGN or INCR? 64.2% of enGene shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 13.7% of enGene shares are held by insiders. Comparatively, 0.2% of InterCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, ENGN or INCR? enGene has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Do analysts prefer ENGN or INCR? enGene currently has a consensus price target of $24.13, indicating a potential upside of 503.13%. Given enGene's stronger consensus rating and higher probable upside, equities research analysts clearly believe enGene is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation & earnings, ENGN or INCR? InterCure has higher revenue and earnings than enGene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$1.52-2.63InterCure$272.67M0.23-$16.83MN/AN/A Does the media refer more to ENGN or INCR? In the previous week, enGene had 2 more articles in the media than InterCure. MarketBeat recorded 4 mentions for enGene and 2 mentions for InterCure. enGene's average media sentiment score of 0.53 beat InterCure's score of 0.05 indicating that enGene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InterCure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryenGene beats InterCure on 9 of the 15 factors compared between the two stocks. Get InterCure News Delivered to You Automatically Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCR vs. The Competition Export to ExcelMetricInterCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.66M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E RatioN/A6.8921.8017.78Price / Sales0.23231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.515.916.443.97Net Income-$16.83M$142.72M$3.21B$247.65M7 Day Performance10.89%4.38%2.85%1.80%1 Month Performance-10.42%-12.76%-8.64%-6.98%1 Year Performance-46.91%-9.69%11.38%1.34% InterCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCRInterCure0.4968 of 5 stars$1.38+0.4%N/A-41.7%$62.66M$272.67M0.00350Short Interest ↑News CoverageENGNenGene3.101 of 5 stars$4.68+4.0%$25.22+438.9%-74.6%$238.57MN/A-8.0731Analyst RevisionAVIRAtea Pharmaceuticals2.3258 of 5 stars$2.78-0.4%$6.88+147.5%-19.9%$237.76MN/A-1.3470News CoverageGap UpESPREsperion Therapeutics3.6751 of 5 stars$1.20-2.4%$6.75+462.5%-48.4%$237.42M$332.31M-1.88200Analyst ForecastCADLCandel Therapeutics2.2866 of 5 stars$4.84+0.4%$21.00+333.9%-16.0%$228.62M$120,000.00-2.8060Short Interest ↑ACBAurora Cannabis0.4233 of 5 stars$4.05+1.0%N/A-23.3%$225.70M$320.81M81.021,340PVLAPalvella Therapeutics3.6347 of 5 stars$20.07-16.3%$43.50+116.7%N/A$221.15M$42.81M-1.66N/AIMMPImmutep1.1029 of 5 stars$1.42-5.3%$8.50+498.6%-31.9%$218.34M$5.14M0.002,021Gap DownOLMAOlema Pharmaceuticals2.7945 of 5 stars$3.18-2.2%$27.67+770.0%-58.7%$217.30MN/A-1.4570Short Interest ↓Positive NewsGap DownCMPXCompass Therapeutics3.3523 of 5 stars$1.57+7.5%$13.38+751.9%+14.4%$217.10M$850,000.00-4.2420Short Interest ↑Gap DownDRUGBright Minds Biosciences2.496 of 5 stars$29.25-8.7%$84.33+188.3%+2,804.4%$206.04MN/A-172.05N/ANews CoverageGap Up Related Companies and Tools Related Companies ENGN Competitors AVIR Competitors ESPR Competitors CADL Competitors ACB Competitors PVLA Competitors IMMP Competitors OLMA Competitors CMPX Competitors DRUG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCR) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INCR Stock Free INCR Stock Alerts